By Yale School of Public Health, McCullough Foundation, The Wellness Company | March 24, 2026
Link to study document
https://zenodo.org/records/19455636
Study Conclusion
In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high proportions of self-reported clinical benefit, with nearly half of participants declaring tumor regression or no current evidence of disease across a heterogeneous population of cancer types. These findings, observed alongside favorable tolerability and strong adherence, support the biological plausibility suggested by preclinical data, indicating this combination may offer therapeutic potential as an adjunctive or repurposed strategy in oncology. However, given the observational design, reliance on self-reported outcomes, and potential for confounding, these results should be interpreted as hypothesis-generating. Rigorous randomized, double blind, placebo-controlled trials are urgently needed to validate safety and efficacy, clarify optimal dosing strategies, and determine the role of this combination across specific cancer types.
Downloadable copy of the study from Real KBrett’s Stack of Stuff
Last Updated on April 14, 2026 by Real KBrett